ARTICLE | Company News

Palatin genitourinary, inflammation news

October 4, 2010 7:00 AM UTC

Palatin will reduce headcount by about 50% to 20 and discontinue discovery research activities to focus on bremelanotide and PL-3994. Palatin plans to begin Phase II testing of bremelanotide for erectile dysfunction (ED) and female sexual dysfunction in 1Q11 and 1H11, respectively. Palatin also plans to submit an IND for PL-3994 to treat acute severe asthma next quarter. Bremelanotide is a melanocortin 4 receptor (MC4R) agonist, and PL-3994 is a long-acting natriuretic peptide receptor A ( NPRA) agonist. ...